Targeted Therapy
Approved for: NSCLC
Biomarker: PD-L1
Atezolizumab (Tecentriq) is a FDA-approved treatment for non-small cell lung cancer that has metastasized. It is used:
- As first-line therapy in adults whose cancer has the PD-L1 protein and does not have a mutation in the EGFR gene or the ALK gene.
- In adults whose cancer has gotten worse during or after treatment with platinum chemotherapy.
- For patients whose cancer has a mutation in the EGFR gene or ALK gene, atezolizumab is used if their disease has gotten worse after treatment with FDA-approved therapy for these mutations.
